Добірка наукової літератури з теми "Trastuzumab therapy"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Trastuzumab therapy".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Trastuzumab therapy"
Park, Juin, Woo Sun Kwon, Sun Kyoung Kang, Tae Soo Kim, Jihyun Hwang, Sang Woo Cho, Kyunggon Kim, Hyun Cheol Chung, and Sun Young Rha. "Abstract 5079: Comparative proteome analysis for predicting the prognosis of trastuzumab-based therapy." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5079. http://dx.doi.org/10.1158/1538-7445.am2022-5079.
Повний текст джерелаOca??a, Alberto, Juan J. Cruz, and Atanasio Pandiella. "Trastuzumab and Antiestrogen Therapy." American Journal of Clinical Oncology 29, no. 1 (February 2006): 90–95. http://dx.doi.org/10.1097/01.coc.0000190274.00570.0a.
Повний текст джерелаEbb, David, Paul Meyers, Holcombe Grier, Mark Bernstein, Richard Gorlick, Steven E. Lipshultz, Mark Krailo, et al. "Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group." Journal of Clinical Oncology 30, no. 20 (July 10, 2012): 2545–51. http://dx.doi.org/10.1200/jco.2011.37.4546.
Повний текст джерелаDormann, Clemens. "Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives." Breast Care 15, no. 6 (2020): 570–78. http://dx.doi.org/10.1159/000512328.
Повний текст джерелаLee, S. W., H. F. Kamaruzaman, and J. Sabirin. "Trastuzumab as An Adjuvant Therapy for Early Breast Cancer." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 70s. http://dx.doi.org/10.1200/jgo.18.31500.
Повний текст джерелаGabric, Ivo Darko, Ljubica Vazdar, Hrvoje Pintaric, Danijel Planinc, Robert Separovic, Mario Stefanovic, Matias Trbusic, Marijana Jazvic, Ozren Vinter, and Zeljko Soldic. "Cardiotoxicity caused by trastuzumab therapy." Cardiologia Croatica 9, no. 9-10 (October 29, 2014): 433. http://dx.doi.org/10.15836/ccar.2014.433.
Повний текст джерелаBrann, Alison M., Melody A. Cobleigh, and Tochi M. Okwuosa. "Cardiovascular Monitoring With Trastuzumab Therapy." JAMA Oncology 2, no. 9 (September 1, 2016): 1123. http://dx.doi.org/10.1001/jamaoncol.2016.1288.
Повний текст джерелаKeene, K. S., L. C. Klepczyk, R. Meredith, A. Forero-Torres, J. T. Carpenter, H. Krontiras, M. Hyatt, Y. Li, and J. F. De Los Santos. "An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events." Journal of Clinical Oncology 29, no. 27_suppl (September 20, 2011): 121. http://dx.doi.org/10.1200/jco.2011.29.27_suppl.121.
Повний текст джерелаOgawa, Lauren, and Deborah Lindquist. "Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease." Case Reports in Oncology 11, no. 3 (December 19, 2018): 855–60. http://dx.doi.org/10.1159/000494264.
Повний текст джерелаHassan, Chadi, Florence Correal, Gabriel Vézina, Louise Yelle, and Jean-Philippe Adam. "Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report." Journal of Oncology Pharmacy Practice 26, no. 7 (March 19, 2020): 1780–84. http://dx.doi.org/10.1177/1078155220910252.
Повний текст джерелаДисертації з теми "Trastuzumab therapy"
Hashimoto, Kenji. "Investigating a role of HER3 in anti-HER2 target therapy in breast cancer." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:39025871-f32f-4e38-bd14-c13dbc9301f6.
Повний текст джерелаKashima(Yamashita), Yoriko. "Studies for maximizing value of antibody drugs against tumors." Kyoto University, 2014. http://hdl.handle.net/2433/193551.
Повний текст джерелаHamel, Sophie. "DARPP-32 expression in acquired resistance of breast cancer cells to trastuzumab." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112631.
Повний текст джерелаNunes, Toni. "Étude pharmacologique préclinique de nanoparticules d’or multimodales dans le cancer du sein HER2 résistant au Trastuzumab." Thesis, Sorbonne Paris Cité, 2019. http://www.theses.fr/2019USPCD053.
Повний текст джерелаHER2-overexpressing metastatic breast cancer is a challenging practice in oncology when it develops resistance to anti-HER2 therapies such as trastuzumab. Gold nanoparticles can be stimulated by near-infrared irradiation to induce ultra-focal hyperthermia. In this context, multimodal gold nanoshells conjugated to an anti-HER2 antibody were specially designed for photothermal therapy to overcome trastuzumab resistance in HER2-overexpressing breast cancer. When gold nanoshells were administered in trastuzumab-resistant HER2-tumor xenografts, no toxicity was observed. In addition, a detailed pharmacokinetic study demonstrated their accumulation in tumors up to 72 hours after administration. These results enabled us to set an effective photothermal treatment protocol by irradiating the mice when the anti-HER2 gold nanoshells accumulated the most in xenografted tumors. In addition, a weekly series of repeated administrations and irradiations for four weeks with a femtosecond-pulsed laser significantly inhibited tumor growth. Then, histological analyzes of tissues showed that this inhibition was due to a direct effect of photothermal therapy on tumor cells, with induction of apoptosis and inhibition of cell proliferation which is consistent with the immune-mediated targeting of tumor cells by anti-HER2 nanoshells. Anti-angiogenic effect was also observed, consistent with a distribution of the gold nanoshells in tumor microvessels. This preclinical study thus supports the use of anti-HER2 gold nanoshells and photothermal therapy to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Honkanen, T. (Tiia). "More efficient use of HER targeting agents in cancer therapy." Doctoral thesis, Oulun yliopisto, 2019. http://urn.fi/urn:isbn:9789526223445.
Повний текст джерелаTiivistelmä Syöpähoidot ovat kehittyneet huomattavasti, kun kohdennetut hoidot ja immunologiset hoidot ovat tulleet perinteisten hoitojen rinnalle. Usein näiden hoitojen hyötyä kuitenkin rajoittaa jo olemassa oleva lääkeresistenssi tai sen kehittyminen, mikä tulisi ottaa huomioon hoitoja suunniteltaessa. Tässä työssä tutkittiin immunologisia merkkiaineita, joilla voitaisiin ennustaa trastutsumabi-hoidon vastetta sekä potilaiden ennustetta levinneessä HER2-positiivisessa rintasyövässä. Tällä hetkellä trastutsumabi-hoitopäätös tehdään pelkän HER2-geenimonistuman mukaan ilman varmuutta siitä, hyötyykö potilas oikeasti hoidosta. Lisäksi tutkimme HER2- ja HER3-reseptorien merkitystä syövän kantasoluille ALK-translokoituneessa ei-pienisoluisessa keuhkosyövässä (NSCLC), sillä syövän kantasolut ovat yksi merkittävimmistä tekijöistä lääkeresistenssin kehittymisessä ja syövän uusiutumisessa. Työssä havaittiin, että kasvaimen keskellä oleva suuri määrä sytotoksisia T-soluja sekä M1-tyypin makrofageja on yhteydessä potilaiden parempaan ennusteeseen ja että kyseiset merkkiaineet ovat toisistaan riippumattomia. Merkkiaineet pystyivät ennustamaan myös taudin etenemistä sekä trastutsumabi-hoitokeskeytyksen pituutta. HER2- ja HER3-proteiinien tuotto lisäsi ALK-translokoituneiden NSCLC-solujen kantasolumaisia ominaisuuksia, jotka puolestaan vähenivät, kun proteiinien tuotto estettiin. Lisäksi HER2-HER3 -riippuvaiset syövän kantasolut säätelivät lääkeresistenssiä kyseisessä taudissa. Työn tulokset viittaavat siihen, että potilaita, joilla on suotuisa kasvaimen immunoprofiili (suuri määrä sytotoksisia T-soluja ja M1-tyypin makrofageja kasvaimen keskellä) pystyttäisiin hoitamaan keveimmillä hoidoilla ja HER2-hoitokeskeytys voisi olla mahdollinen näillä potilailla. Lisäksi työ korostaa HER2- ja HER3-reseptorien kohdentamista syövän kantasolumaisten solujen tehokkaamman tuhoamisen saavuttamiseksi
Huomautus/Notice Painetussa virheelliset ISBN -tunnukset: ISBN (print) 978-952-42-2343-8 pitäisi olla 978-952-62-2343-8. ISBN (PDF) 978-952-42-2344-5 pitäisi olla 978-952-62-2344-5. Printed version has incorrect ISBNs: ISBN (print) 978-952-42-2343-8 it should be 978-952-62-2343-8. ISBN (PDF) 978-952-42-2344-5 it should be 978-952-62-2344-5
Khalili, Boroojeni Parisa. "Evaluation of the effect of trastuzumab (Herceptin) on the development and progression of breast cancer associated skeletal metastasis." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112523.
Повний текст джерелаThe biological characteristics of cancer cells along with the targeting properties of immune system offer a novel approach in the treatment of breast cancer. Directed against HER-2/nue oncogene, the recombinant humanized monoclonal antibody, Trastuzumab (Herceptin), has shown significant clinical benefits for the treatment of HER-2 positive metastatic breast cancer.
In the present study, the effects of Herceptin and its molecular mechanism of action in abrogating the development and progression of osteolytic bone metastasis is investigated in an experimental mouse model of skeletal metastasis using human breast cancer cells BT-474 which are known to express high levels of HER-2. Treatment of BT-474 cells with Herceptin caused a dose dependent decrease in cell proliferation. In in vivo studies BT-474 cells were injected by into the left ventricle of female BALB/c nu/nu mice. Intraperitoneal infusion of Herceptin from the day of tumor cell inoculation or at the time of radiologically detectable skeletal metastasis either slowed the development or prevented the progression of skeletal metastasis as compared to control groups of animals receiving non-specific IgG. Bone histological analysis of long bones showed the ability of Herceptin to reduce the ratio of tumor volume to bone volume as well as mitotic index when Herceptin treatment was initiated from the day of tumor cell inoculation. Immunohistochemical analysis of long bones showed a significantly lower level of activated (phosphorylated) MAPK in bones of Herceptin treated animals. These studies demonstrate the ability of Herceptin to inhibit the development and abrogate the progression of skeletal metastasis associated with breast cancer by blocking the HER-2 mediated signaling pathways.
Zwingenberger, Gwen [Verfasser], Birgit [Akademischer Betreuer] Luber, Birgit [Gutachter] Luber, and Michael [Gutachter] Schemann. "Molecular and phenotypical characterization of gastric cancer cell lines and validation of potential resistance factors to trastuzumab therapy / Gwen Zwingenberger ; Gutachter: Birgit Luber, Michael Schemann ; Betreuer: Birgit Luber." München : Universitätsbibliothek der TU München, 2019. http://d-nb.info/118625663X/34.
Повний текст джерелаAshok, Mahima. "Analysis of HER2 testing in breast cancer." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2009. http://hdl.handle.net/1853/29711.
Повний текст джерелаCommittee Chair: Griffin, Paul; Committee Member: Butera, Robert; Committee Member: Halpern, Michael; Committee Member: Nichols, Richard; Committee Member: Vidakovic, Brani. Part of the SMARTech Electronic Thesis and Dissertation Collection.
Reetz, Christina [Verfasser]. "In-vitro-Untersuchungen zum Potenzial von radioaktiv markiertem Trastuzumab für die Diagnostik und Therapie von Mammakarzinomen / Christina Reetz." Lübeck : Zentrale Hochschulbibliothek Lübeck, 2010. http://d-nb.info/100811040X/34.
Повний текст джерелаFauser, Sophia Mignon [Verfasser]. "Einfluss einer adjuvanten Trastuzumab-Therapie sowie der palliativen Erstlinientherapie auf das progressionsfreie Überleben und Gesamtüberleben bei Patientinnen mit metastasiertem HER2-überexprimierendem Mammakarzinom / Sophia Mignon Fauser." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2020. http://d-nb.info/1218077204/34.
Повний текст джерелаКниги з теми "Trastuzumab therapy"
Drugs for HER2-positive breast cancer. Basel: Springer, 2011.
Знайти повний текст джерелаCassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Amen Sibtain. Colorectal cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0015_update_001.
Повний текст джерелаSibilia, Maria, Christoph C. Zielinski, Rupert Bartsch, and Thomas W. Grunt. Drugs for HER-2-Positive Breast Cancer. Springer Basel AG, 2013.
Знайти повний текст джерелаЧастини книг з теми "Trastuzumab therapy"
Perez, Edith A., Frances M. Palmieri, and Shelly M. Brock. "Trastuzumab." In Adjuvant Therapy for Breast Cancer, 181–96. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-75115-3_12.
Повний текст джерелаPegram, Mark D., Gottfried Konecny, and Dennis J. Slamon. "The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer." In Advances in Breast Cancer Management, 57–75. Boston, MA: Springer US, 2000. http://dx.doi.org/10.1007/978-1-4757-3147-7_4.
Повний текст джерелаOmland, Torbjørn. "Trastuzumab-related cardiotoxicity: epidemiology, surveillance, management, prophylaxis, and prognosis." In ESC CardioMed, 1167–70. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0291.
Повний текст джерелаSwapna, Mudrakola, and Nagaratna P. Hegde. "Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle." In Encyclopedia of Data Science and Machine Learning, 2617–35. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-9220-5.ch157.
Повний текст джерелаBando, Hideaki, Takahiro Kinoshita, Yasutoshi Kuboki, Atsushi Ohtsu, and Kohei Shitara. "Gastric cancer." In Oxford Textbook of Oncology, 388–407. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0037.
Повний текст джерелаCrook, Tim, Su Li, and Peter Harper. "Medical management of breast cancer." In Oxford Textbook of Medicine, edited by Tim Eisen, 505–8. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0051.
Повний текст джерелаAladwani, Afrah. "Comparing Trastuzumab-Related Cardiotoxicity Between Elderly and Younger Patients with Breast Cancer: A Prospective Cohort Study." In 2nd International E-Conference on Cancer Science and Therapy. United Research Forum, 2021. http://dx.doi.org/10.51219/urforum.2021.afrah-aladwani.
Повний текст джерелаТези доповідей конференцій з теми "Trastuzumab therapy"
Gradishar, W., S. Wroblewski, Y. Huang, C. Harvey, N. Franklin, and S. Johnston. "Abstract OT1-1-09: ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-ot1-1-09.
Повний текст джерелаSorace, Anna G., C. Chad Quarles, Violeta Sanchez, and Thomas E. Yankeelov. "Abstract 4237: Decreased hypoxia in a HER2+breast cancer model following trastuzumab therapy." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4237.
Повний текст джерелаNg, D., I. Ferrusi, H. Khong, C. Earle, M. Trudeau, D. Marshall, and N. Leighl. "Abstract P5-18-14: Cardiac monitoring during adjuvant trastuzumab therapy for breast cancer." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p5-18-14.
Повний текст джерелаBaselga, J., K. Imadalou, V. Paton, D. Gray, and S. Swain. "Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3138.
Повний текст джерелаKumar, VNC, P. Kavsak, S. Rask, SD Mukherjee, P. Ellis, and B. Dhesy-Thind. "OT1-02-13: Cardiac Biomarkers on Trastuzumab (Cabot Trial): Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-ot1-02-13.
Повний текст джерелаGeyer, CE, C.-S. Huang, MS Mano, S. Loibl, EP Mamounas, M. Untch, N. Wolmark, et al. "Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-gs1-10.
Повний текст джерелаMurthy, RK, AS Raghavendra, KR Hess, CH Barcenas, B. Lim, SL Moulder, SH Giordano, et al. "Abstract P6-17-04: 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-17-04.
Повний текст джерелаTorrisi, R., S. Dellapasqua, G. Cancello, A. Balduzzi, E. Montagna, R. Ghisini, M. Iorfida, et al. "Preoperative Therapy with Pegylated Liposomal Doxorubicin, Cisplatin and Infusional Fluoruracil + Trastuzumab (±Endocrine Therapy) in Locally Advanced HER2 Positive Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-1097.
Повний текст джерелаMarla, S., P. Roxburgh, P. Burton, S. Stallard, E. Mallon, P. Canney, and T. Cooke. "HER2 positive early breast cancers: tumour demographics and trastuzumab therapy in the real-world." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3159.
Повний текст джерелаBuxton, Meredith, Angela M. DeMichele, Stephen Chia, Laura van't Veer, Jo Chien, Anne Wallace, Henry Kaplan, et al. "Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-ct106.
Повний текст джерелаЗвіти організацій з теми "Trastuzumab therapy"
Kohrt, Holbrook. Augmenting Trastuzumab Therapy Against Breast Cancer Through Selective Activation of NK Cells. Fort Belvoir, VA: Defense Technical Information Center, October 2012. http://dx.doi.org/10.21236/ada573699.
Повний текст джерелаKohrt, Holbrook. Augmenting Trastuzumab Therapy Against Breast Cancer Through Selective Activation of NK Cells. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada595679.
Повний текст джерелаZhao, YiHao, and Dongbin Zhang. Efficacy and safety of trastuzumab combined with neoadjuvant chemotherapy in Chinese patients with HER-2 positive breast cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0003.
Повний текст джерела